Higher IMPDH1 expression is linked to poorer prognosis in renal cancer, liver cancer, urothelial cancer, glioma, and cervical cancer, while high IMPDH2 levels associate with poor prognosis in liver cancer. This evidence concerns the gene IMPDH2 and renal carcinoma.